Hepsal (Heparin Sodium)

Hepsal is employed in clinical settings where inhibition of clot formation is required. It is commonly used for:

• Prevention of venous thromboembolism in patients undergoing orthopedic or abdominal surgery.
• Treatment of acute deep‑vein thrombosis and pulmonary embolism.
• Prophylaxis of clot formation during hemodialysis or extracorporeal circulation.
• Maintaining catheter patency by preventing intraluminal thrombosis.
• Managing hypercoagulable states in hospitalized patients.

Hepsal may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common

• Minor bleeding at injection site or from mucous membranes.
• Small bruises or hematomas.
• Nausea or mild abdominal discomfort.
• Transient elevation of liver enzymes.
• Mild headache.

Serious

• Major hemorrhage, including gastrointestinal or intracranial bleeding.
• Heparin‑induced thrombocytopenia (HIT).
• Severe allergic reactions such as anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Acute renal failure secondary to bleeding complications.

Use of Hepsal requires careful assessment of bleeding risk and patient history. Important considerations include:

• Baseline and periodic monitoring of platelet counts to detect heparin‑induced thrombocytopenia.
• Regular assessment of coagulation parameters (e.g., activated partial thromboplastin time).
• Caution in patients with a history of recent surgery, trauma, or active bleeding.
• Adjust dosing in individuals with renal impairment or hepatic dysfunction.
• Avoid use in patients with known hypersensitivity to heparin or pork‑derived products.
• Pregnancy and lactation status should be evaluated, as safety data are limited.

Hepsal can interact with several medications that affect hemostasis or renal clearance. Interaction guidance includes:

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring.
• Administration with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs, which may increase bleeding risk.
• Combination with thrombolytic therapy (e.g., alteplase) due to additive hemorrhagic potential.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair platelet function.
• Certain antibiotics (e.g., cefotetan) that have been associated with HIT.
• High‑dose corticosteroids, which may affect coagulation balance.
• Renally cleared drugs that could accumulate if renal function declines during therapy.